{"id":"NCT03126227","sponsor":"Aimmune Therapeutics, Inc.","briefTitle":"Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)","officialTitle":"Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children Ages 4 to 17 Years (RAMSES)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-05-08","primaryCompletion":"2018-08-31","completion":"2018-09-23","firstPosted":"2017-04-24","resultsPosted":"2021-11-02","lastUpdate":"2021-11-02"},"enrollment":506,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Peanut Allergy"],"interventions":[{"type":"BIOLOGICAL","name":"AR101","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"AR101 Powder Provided in Capsules","type":"ACTIVE_COMPARATOR"},{"label":"Placebo powder","type":"PLACEBO_COMPARATOR"}],"summary":"This is a multicenter, randomized, double-blind, placebo-controlled safety study of AR101 using the characterized oral desensitization immunotherapy (CODITâ„¢) regimen in peanut-allergic children.","primaryOutcome":{"measure":"Frequency of Treatment Emergent Adverse Events, Including Serious Adverse Events","timeFrame":"Approximately 6 months","effectByArm":[{"arm":"AR101 Powder Provided in Capsules","deltaMin":334,"sd":null},{"arm":"Placebo Powder","deltaMin":159,"sd":null}],"pValues":[]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":67,"countries":["United States","Canada"]},"refs":{"pmids":["34389504"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":337},"commonTop":["Abdominal pain","Throat irritation","Pruritus","Abdominal discomfort","Vomiting"]}}